As autumn settles in across the Northern Hemisphere, it’s the perfect moment to look back on a summer of momentum and milestones at Open Pharma.
We kicked off quarter 3 with a thought-provoking topic meeting from Neil Pakenham-Walsh (Coordinator of Healthcare Information For All [HIFA]), exploring the global consultation report for the World Health Organization on Universal access to reliable healthcare information: a global consultation.
The Open Pharma team at Oxford PharmaGenesis also shared the results of our Creative Commons (CC) licence landscape project with our Members and Supporters. This deep dive into the transparency and findability of information about CC licence options uncovered new insights into the challenges in achieving of open licensing for pharma-sponsored publications. The results of this analysis will be submitted to the 2026 European Meeting of the International Society for Medical Publication Professionals (ISMPP), along with an encore of the Plain Language Summary of Publication guidance abstract presented at ISMPP Annual 2025 and a project sponsored by Oxford PharmaGenesis that explored transparency in the disclosure of article processing charges and content reuse permissions, restrictions and costs.
In September, we were delighted to welcome Bayer as the latest Open Pharma Supporter and celebrated the launch of the HIFA open access (OA) working group. This working group will build on the outcomes of the healthcare professional OA survey conducted earlier this year to improve knowledge about and uptake of OA among different researcher users and professions.
We’re now looking ahead to two flagship events in the coming months; Open Pharma Day and our Annual General Meeting. We invite our Members and Supporters to contact us for more information about these events.
Make sure you’re following us on LinkedIn and Bluesky to keep up to date with all of our activities.
Learn more about what we’ve been up to below or click here.
